 |
|
Welcome to the SWOG website
SWOG is a cancer research cooperative group that designs and conducts multidisciplinary clinical trials to improve the practice of medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. Primary support for SWOG comes from the National Cancer Institute.
If you are not a member of SWOG, we invite you to our Visitors pages, which contain information about our Group we hope you will find interesting and useful.
|
|
| |
S0221: low-dose weekly paclitaxel as effective as biweekly
S0221 results show lower dose, weekly adjuvant paclitaxel (Taxol) for women with early-stage breast cancer was comparable to the standard dose, biweekly regimen, but caused substantially fewer side effects, G. Thomas Budd, M.D., reported today at the morning press briefing at the ASCO 2013 Annual Meeting in Chicago. He presents CRA1008 Monday at an oral abstract session from 12:15 - 12:30 pm CDT, N Hall B1.
Visit this page
|
|
SWOG Twitter Feed
|
 |
|
|
 |
| |
The Hope Foundation supports the Group's work. |
|
|
 |
|
 |
Links to featured sections
|
|
 |
| |
|
